Mind + Muscle

technical minds + legal muscle


dig deep

Legal Experts Assess Potential Impact of GeneDx's IPR Challenge of Myriad Patents

  • 08.27.14
  • Turna Ray
  • GenomeWeb’s Pharmacogenomics Reporter

GenomeWeb’s Pharmacogenomics Reporter discussed GeneDx's decision to file for inter partes review (IPR) of 11 patents held by, or licensed to, Myriad Genetics. Turna Ray reports that IPR of these 11 patents would require the USPTO to determine whether or not prior art undermines certain patent claims.  Sterne, Kessler, Goldstein & Fox filed these IPRs on behalf of GeneDx.

To read the full article, click here.

Related People

Related Services

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.